dipyridamole has been researched along with Asymmetric Septal Hypertrophy, Familial in 1 studies
Dipyridamole: A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752)
dipyridamole : A pyrimidopyrimidine that is 2,2',2'',2'''-(pyrimido[5,4-d]pyrimidine-2,6-diyldinitrilo)tetraethanol substituted by piperidin-1-yl groups at positions 4 and 8 respectively. A vasodilator agent, it inhibits the formation of blood clots.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Olivotto, I | 1 |
| Girolami, F | 1 |
| Sciagrà , R | 1 |
| Ackerman, MJ | 1 |
| Sotgia, B | 1 |
| Bos, JM | 1 |
| Nistri, S | 1 |
| Sgalambro, A | 1 |
| Grifoni, C | 1 |
| Torricelli, F | 1 |
| Camici, PG | 1 |
| Cecchi, F | 1 |
1 other study available for dipyridamole and Asymmetric Septal Hypertrophy, Familial
| Article | Year |
|---|---|
Microvascular function is selectively impaired in patients with hypertrophic cardiomyopathy and sarcomere myofilament gene mutations.
Topics: Actin Cytoskeleton; Adolescent; Adult; Ammonia; Cardiac Myosins; Cardiomyopathy, Hypertrophic, Famil | 2011 |